Novel ERbeta agonists for the treatment of gliomas

用于治疗神经胶质瘤的新型 ERbeta 激动剂

基本信息

项目摘要

DESCRIPTION (provided by applicant): Glioblastoma (GBM) are the most malignant primary brain tumor and patients with GBM (grade IV glioma) have a survival time of approximately 14 months. Estrogen plays a crucial role during brain development and differentiation. Epidemiological and experimental evidence suggests tumor suppressive role of estrogen on brain tumors. However, the molecular mechanisms by which estrogen mediate protection against GBM remains unknown. Estrogen functions are mediated by two ER-subtypes: ER� that functions as tumor promoter and ER� that functions as a tumor suppressor. Emerging evidence suggest that GBM cells express ER�; however, the clinical utility of ER� is limited due to lack of mechanistic insights and agents that specifically target ER�. Recent studies have identified liquiritigenin (LIQ) isolated from the plant Glycyrrhiza uralensis and synthetic compound LY500307 (LY) as selective ER� specific agonists. The objective of this proposal is to translate evolving scientific evidence and the functional role of ER� into a clinical strategy to suppress GBM by employing ER� specific agonists. Our central hypothesis is that ER� agonists inhibit the growth of GBM by enhancing tumor suppressive functions of ER� and that ER� agonists promote differentiation of glioma stem cells leading to increased therapeutic efficacy. The hypothesis is supported by our preliminary studies that (1) ER�-mediated mechanisms play a tumor suppressive function; (2) ER� agonists suppress GBM cell proliferation in vitro and in vivo; (3) ER�-agonists upregulate expression of ER� (4) ER�-agonists inhibit growth of Glioma Stem Cells and promote their differentiation. To investigate the proposed hypotheses, in aim 1, we will test the significance and therapeutic efficacy of ER� agonists to inhibit the growth of GBM. In aim 2, we will determine the molecular mechanism(s) of ER� agonists in the suppression of GBM. In aim 3, we will investigate the role of ER� agonists in the differentiation of Glioma Stem Cells. Understanding how ER� functions as a tumor suppressor in GBM will be useful in maximizing treatment opportunities for GBM. The proposed research is innovative due to the novelty of the concepts involving ER� agonists and their therapeutic potential in the suppression of GBM. This proposal will establish the significance and therapeutic potential of ER� signaling in GBM progression and thus create a new paradigm for the use of ER� specific ligands (LIQ and LY) for curbing GBM progression. Since ER� agonists currently in clinical trials are well tolerated with limited side effects and good blood-brain barrier permeability, identification of ER� agonists as a therapeutic agent can be readily adapted to clinical use as a monotherpy or in combination with current chemotherapies and radiation, thereby providing an additional tool for enhancing survival in GBM patients. Further, the results from these studies have the potential to provide novel insights into the mechanisms of ER� mediated tumor suppression at the molecular level.
描述(由申请人提供):胶质母细胞瘤(GBM)是最恶性的原发性脑肿瘤,GBM(IV级胶质瘤)患者的生存时间约为14个月。雌激素在大脑发育和分化过程中起着至关重要的作用。流行病学和实验证据表明雌激素对脑肿瘤具有肿瘤抑制作用。然而,雌激素介导对GBM的保护作用的分子机制仍然未知。雌激素的功能由两种ER亚型介导:作为肿瘤促进剂的ER β和作为肿瘤抑制剂的ER β。新出现的证据表明,GBM细胞表达ER β;然而,由于缺乏专门针对ER β的机制见解和药物,ER β的临床用途有限。最近的研究已经确定从植物甘草中分离的甘草素(LIQ)和合成化合物LY 500307(LY)是选择性ER β特异性激动剂。该提案的目的是将不断发展的科学证据和ER β的功能作用转化为通过采用ER β特异性激动剂抑制GBM的临床策略。我们的中心假设是ER β激动剂通过增强ER β的肿瘤抑制功能来抑制GBM的生长,并且ER β激动剂促进胶质瘤干细胞的分化,从而提高治疗效果。我们的初步研究支持这一假设:(1)ER β介导的机制发挥肿瘤抑制作用;(2)ER β激动剂抑制GBM细胞的体外和体内增殖;(3)ER β激动剂上调ER β的表达;(4)ER β激动剂抑制胶质瘤干细胞的生长并促进其分化。为了研究所提出的假设,在目标1中,我们将测试ER β激动剂抑制GBM生长的意义和治疗效果。在目标2中,我们将确定ER β激动剂抑制GBM的分子机制。在目标3中,我们将研究ER β激动剂在胶质瘤干细胞分化中的作用。了解ER如何在GBM中作为肿瘤抑制因子发挥作用将有助于最大限度地增加GBM的治疗机会。由于涉及ER β激动剂及其抑制GBM的治疗潜力的概念的新奇,拟议的研究是创新的。该提案将确立ER β信号在GBM进展中的意义和治疗潜力,从而为使用ER β特异性配体(LIQ和LY)抑制GBM进展创造新的范例。由于目前在临床试验中的ER β激动剂耐受性良好,副作用有限,血脑屏障通透性良好,因此ER β激动剂作为治疗剂的鉴定可以很容易地适用于临床使用,作为单一疗法或与目前的化疗和放疗联合使用,从而为提高GBM患者的生存率提供了额外的工具。此外,这些研究的结果有可能在分子水平上为ER介导的肿瘤抑制机制提供新的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrew Jacob Brenner其他文献

Andrew Jacob Brenner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrew Jacob Brenner', 18)}}的其他基金

Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma
开发用于治疗胶质母细胞瘤的有效雌激素受体β激动剂
  • 批准号:
    10594832
  • 财政年份:
    2023
  • 资助金额:
    $ 31.02万
  • 项目类别:
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma
铼纳米脂质体 (RNL186) 治疗胶质母细胞瘤的临床开发
  • 批准号:
    10242665
  • 财政年份:
    2019
  • 资助金额:
    $ 31.02万
  • 项目类别:
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma
铼纳米脂质体 (RNL186) 治疗胶质母细胞瘤的临床开发
  • 批准号:
    10013171
  • 财政年份:
    2019
  • 资助金额:
    $ 31.02万
  • 项目类别:
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma
铼纳米脂质体 (RNL186) 治疗胶质母细胞瘤的临床开发
  • 批准号:
    10687851
  • 财政年份:
    2019
  • 资助金额:
    $ 31.02万
  • 项目类别:
Omega-3 Fatty Acid Modulation of Obesity-Induced Aromatase Expression
Omega-3 脂肪酸对肥胖诱导的芳香酶表达的调节
  • 批准号:
    9035932
  • 财政年份:
    2015
  • 资助金额:
    $ 31.02万
  • 项目类别:
Omega-3 Fatty Acid Modulation of Obesity-Induced Aromatase Expression
Omega-3 脂肪酸对肥胖诱导的芳香酶表达的调节
  • 批准号:
    9198761
  • 财政年份:
    2015
  • 资助金额:
    $ 31.02万
  • 项目类别:
Novel ERbeta agonists for the treatment of gliomas
用于治疗神经胶质瘤的新型 ERbeta 激动剂
  • 批准号:
    8762188
  • 财政年份:
    2014
  • 资助金额:
    $ 31.02万
  • 项目类别:
Phase 2 Study of TH-302 for the Treatment of Glioblastoma
TH-302 治疗胶质母细胞瘤的 2 期研究
  • 批准号:
    8748318
  • 财政年份:
    2014
  • 资助金额:
    $ 31.02万
  • 项目类别:
Phase 2 Study of TH-302 for the Treatment of Glioblastoma
TH-302 治疗胶质母细胞瘤的 2 期研究
  • 批准号:
    9108161
  • 财政年份:
    2014
  • 资助金额:
    $ 31.02万
  • 项目类别:
Phase 2 Study of TH-302 for the Treatment of Glioblastoma
TH-302 治疗胶质母细胞瘤的 2 期研究
  • 批准号:
    9316339
  • 财政年份:
    2014
  • 资助金额:
    $ 31.02万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 31.02万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 31.02万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 31.02万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 31.02万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 31.02万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 31.02万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 31.02万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 31.02万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 31.02万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 31.02万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了